Daidzein is a very good candidate for treating cardio-cerebrovascular diseases, but its poor oral absorption and bioavailability limit its curative efficacy. In this work, daidzein-loaded solid lipid nanoparticles (SLNs) with PEGylated phospholipid as stabilizer were successfully prepared by hot hom
Apolipoprotein(a) phenotypes in cardio-cerebrovascular diseases
β Scribed by Zhuang Yiyi; Li Janjun; Wang Junjun
- Publisher
- Elsevier Science
- Year
- 1994
- Tongue
- English
- Weight
- 266 KB
- Volume
- 67-68
- Category
- Article
- ISSN
- 0009-3084
No coin nor oath required. For personal study only.
β¦ Synopsis
We report apolipoprotein(a) (apo(a)) phenotypes of 69 myocardial infarction survivors and 56 stroke patients, and compare them with those of 190 healthy Chinese. The results indicate that the distribution of apo(a) phenotype frequency in cardio-cerebrovascular disease patients is different from those of controls. The frequency of the phenotypes B, SI and S 2 in patients is remarkably higher than those in controls within the same single-band apo(a) phenotype. Moreover, the Lp(a) serum concentrations in CCVD patients are significantly higher than those in controls within the same single-band apo(a) phenotype. The apo(a) phenotype analyses of two pedigrees are shown as a typical autosomal dominant inheritance.
π SIMILAR VOLUMES
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL) particle in which apolipoprotein B-100 (apoB) is attached to a glycoprotein called apolipoprotein(a) [apo(a)]. Apo(a) has several genetically determined phenotypes differing in molecular weight, to which Lp(a) concentrations in plasma are inv